The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before?
Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.
The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.
Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.
A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.
The US has joined consensus on a World Health Organization resolution on the global handling of the COVID-19 pandemic, but disassociated itself from the IP and reproductive health services wording within the resolution.
The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.